RCG
ACTU

Rock Creek Group’s Actuate Therapeutics ACTU Stock Holding History

Rock Creek Group’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$60.1K Hold
39,263
– – 0.01% 56
2026
Q1 		$108K Buy
39,263
+17,504
+80% +$72.5K 0.01% 53
2025
Q4 		$133K Buy
+21,759
New +$149K 0.01% 48

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $304M AUM 15.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $159M AUM 34.17% 1-Year Est. Return

Rock Creek Group's ACTU Position: Q2 2026 in Review

Rock Creek Group held its Actuate Therapeutics (ACTU) position steady in Q2 2026 at 39,263 shares worth $60.1K. The position accounts for 0.01% of the portfolio, ranked #56.

Rock Creek Group first reported a position in ACTU in Q4 2025 and has held it in 3 quarters since. The position peaked at $133K in Q4 2025. 64 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • Rock Creek Group held 39,263 shares of Actuate Therapeutics worth $60.1K as of Q2 2026.
  • Rock Creek Group left its Actuate Therapeutics share count unchanged in Q2 2026.
  • Actuate Therapeutics made up 0.01% of Rock Creek Group's portfolio in Q2 2026, its #56 holding.
  • Rock Creek Group first reported a position in Actuate Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Rock Creek Group's Actuate Therapeutics position peaked at $133K in Q4 2025.
  • 64 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on Rock Creek Group's 13F filing for Q2 2026, filed 3 Aug 2026.